What a Breakthrough Infection Looks Like After Intradermal Vaccination

The Swedish case series focuses on a question that national case counts cannot answer in enough detail: when mpox occurs after intradermal MVA-BN vaccination, what does “less severe” look like in the patient’s actual illness? The study is valuable because it follows breakthrough cases through a structured clinical assessment. It is also deliberately bounded. Its results describe a specialized Stockholm population and an observational comparison, not a guaranteed course for every person who has received two doses of JYNNEOS/MVA-BN.

The distinction matters because a breakthrough infection is not a single event with a single outcome. A person may develop a small number of lesions or many, have disease in one anatomical region or several, need only over-the-counter pain medicine or require prescription treatment, and remain an outpatient or need admission. Counting the infection alone hides those differences. The Swedish researchers used a validated severity score to make them visible.

The cohort was defined before the comparison was made

The study reviewed laboratory-confirmed mpox diagnosed between January 2024 and October 2025 at a major HIV and sexual-health center in Stockholm. The clinic serves transgender people and cisgender men who have sex with men, provides HIV care, and functions as a regional MVA-BN vaccination center. That setting gives the researchers detailed clinical and vaccination records, but it also shapes the population represented in the results.

During the study period, 95 cases were reported to the Stockholm County Medical Officers. Eighty patients were diagnosed and treated at the hospital, and one was excluded because less than two weeks had elapsed since vaccination. The final analysis included 79 patients: 32 unvaccinated and 47 with some prior smallpox or mpox vaccination. Among the vaccinated patients, 30 had received MVA-BN only. Twenty-five of those had completed two doses, while five had received one dose. The other 17 had childhood smallpox vaccination, sometimes combined with one or two MVA-BN doses.

All MVA-BN doses in this cohort were administered intradermally. That detail is central to the study’s contribution. Intradermal administration places a fractional dose into the skin and was used as a dose-sparing strategy during a period of limited supply. The Swedish data therefore show what happened among observed breakthrough cases after an intradermal program. They do not compare intradermal and subcutaneous vaccination head to head, and they do not show whether one route is superior.

The primary severity comparison used the 32 unvaccinated patients and the 30 patients vaccinated with MVA-BN only. This choice avoids treating childhood smallpox vaccination as though it were the same exposure as a recent MVA-BN series. It also keeps the main comparison closer to the question of how MVA-BN relates to disease severity. The 17 patients with smallpox vaccination histories remain informative, but their age and vaccination history differ from those of the other groups and make a simple pooled comparison misleading.

The cohort was not a random sample of all people with mpox. Most patients were cisgender men who have sex with men, and the clinic had particular expertise in HIV and sexual health.